CEO-linked entity buys 10,000 Edesa Biotech (EDSA) shares

Rhea-AI Filing Summary

Edesa Biotech, Inc. director and Chief Executive Officer Pardeep Nijhawan reported an indirect open-market purchase of 10,000 common shares on March 3, 2026 at a price per share of 3.63, through Pardeep Nijhawan Medicine Professional Corporation.

The filing also reports Nijhawan’s direct and additional indirect holdings in common shares, including positions held via The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.

Insider Trade Summary

Net Buyer: 10,000 shares ($36,300)

Net Buy 5 txns

Insider Nijhawan Pardeep

Role Chief Executive Officer

Bought 10,000 shs ($36K)

Type	Security	Shares	Price	Value
Purchase	Common Shares	10,000	$3.63	$36K
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--
holding	Common Shares	--	--	--

Holdings After Transaction: Common Shares — 382,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation); Common Shares — 627,813 shares (Direct)

Footnotes (1)

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

C/O EDESA BIOTECH INC.

100 SPY COURT

(Street)

MARKHAM A6 L3R 5H6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	03/03/2026		P		10,000	A	$3.63	382,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(1)
Common Shares								627,813	D
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(1)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160 Ontario Inc.(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

2. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Edesa Biotech (EDSA) report for Pardeep Nijhawan?

Edesa Biotech reported that an entity associated with CEO Pardeep Nijhawan bought 10,000 common shares on March 3, 2026. The shares were purchased in the open market at a price per share of 3.63 through Pardeep Nijhawan Medicine Professional Corporation.

Was the Edesa Biotech insider trade by Pardeep Nijhawan direct or indirect?

The March 3, 2026 purchase was reported as an indirect transaction for Pardeep Nijhawan. The 10,000 common shares were acquired by Pardeep Nijhawan Medicine Professional Corporation, which is associated with him rather than held in his name directly.

What additional Edesa Biotech (EDSA) holdings are reported for Pardeep Nijhawan?

The filing lists direct holdings of common shares and several indirect holdings. These include shares held by The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., reflecting various entities connected to Nijhawan’s pecuniary interests.

How does Pardeep Nijhawan describe his beneficial ownership of Edesa Biotech shares?

Pardeep Nijhawan disclaims beneficial ownership of shares held through his related entities and trust, except to the extent of his pecuniary interest. The filing states this disclaimer applies for Section 16 and for any other purpose regarding the reported shares.

What was the price per share in the Edesa Biotech insider purchase on March 3, 2026?

The reported open-market purchase on March 3, 2026 was executed at a price per share of 3.63. This price applies to the 10,000 common shares acquired indirectly through Pardeep Nijhawan Medicine Professional Corporation, as disclosed in the Form 4 filing.